TY - JOUR
T1 - Antibody-Conjugated Nanoparticles for Therapeutic Applications
AU - Cardoso, Maria Margarida Canas Mendes de Almeida
AU - Peça, Inês N.
AU - Roque, Ana Cecília Afonso
N1 - Ines Peca is grateful for financial support from Fundacao para a Ciencia e a Tecnologia through contract SFRH/BD/48773/2008. This work has been supported by Fundacao para a Ciencia e a Tecnologia through grant no. PEst-C/EQB/LA0006/2011.
PY - 2012
Y1 - 2012
N2 - A great challenge to clinical development is the delivery of chemotherapeutic agents, known to cause severe toxic effects, directly to diseased sites which increase the therapeutic index whilst minimizing off-target side effects. Antibody-conjugated nanoparticles offer great opportunities to overcome these limitations in therapeutics. They combine the advantages given by the nanoparticles with the ability to bind to their target with high affinity and improve cell penetration given by the antibodies. This specialized vehicle, that can encapsulate several chemotherapeutic agents, can be engineered to possess the desirable properties, allowing overcoming the successive physiological conditions and to cross biological barriers and reach a specific tissue or cell. Moreover, antibody-conjugated nanoparticles have shown the ability to be internalized through receptor-mediated endocytosis and accumulate in cells without being recognized by the P-glycoprotein, one of the main mediators of multi-drug resistance, resulting in an increase in the intracellular concentration of drugs. Also, progress in antibody engineering has allowed the manipulation of the basic antibody structure for raising and tailoring specificity and functionality. This review explores recent developments on active drug targeting by nanoparticles functionalized with monoclonal antibodies (polymeric micelles, liposomes and polymeric nanoparticles) and summarizes the opportunities of these targeting strategies in the therapy of serious diseases (cancer, inflammatory diseases, infectious diseases, and thrombosis).
AB - A great challenge to clinical development is the delivery of chemotherapeutic agents, known to cause severe toxic effects, directly to diseased sites which increase the therapeutic index whilst minimizing off-target side effects. Antibody-conjugated nanoparticles offer great opportunities to overcome these limitations in therapeutics. They combine the advantages given by the nanoparticles with the ability to bind to their target with high affinity and improve cell penetration given by the antibodies. This specialized vehicle, that can encapsulate several chemotherapeutic agents, can be engineered to possess the desirable properties, allowing overcoming the successive physiological conditions and to cross biological barriers and reach a specific tissue or cell. Moreover, antibody-conjugated nanoparticles have shown the ability to be internalized through receptor-mediated endocytosis and accumulate in cells without being recognized by the P-glycoprotein, one of the main mediators of multi-drug resistance, resulting in an increase in the intracellular concentration of drugs. Also, progress in antibody engineering has allowed the manipulation of the basic antibody structure for raising and tailoring specificity and functionality. This review explores recent developments on active drug targeting by nanoparticles functionalized with monoclonal antibodies (polymeric micelles, liposomes and polymeric nanoparticles) and summarizes the opportunities of these targeting strategies in the therapy of serious diseases (cancer, inflammatory diseases, infectious diseases, and thrombosis).
KW - infectious diseases therapy
KW - tumour therapy
KW - inflammatory diseases therapy
KW - targeted drug delivery
KW - antibody-conjugated nanoparticles
KW - surfacemodification
KW - Active targeting
KW - Active targeting
KW - antibody-conjugated nanoparticles
KW - infectious diseases therapy
KW - inflammatory diseases therapy;
KW - surface modification
KW - targeted drug delivery
KW - tumour therapy
U2 - 10.2174/092986712800784667
DO - 10.2174/092986712800784667
M3 - Review article
C2 - 22612698
SN - 0929-8673
VL - 19
SP - 3103
EP - 3127
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
IS - 19
ER -